China603983.CG▼2
Marumi Bio first-half 2026 net profit 155 million yuan
Marumi Bio disclosed its 2026 semi-annual report on August 29. In the first half, it achieved total operating revenue of 1.663 billion yuan, down 5.76 percent year on year. Net profit attributable to the parent company was 155 million yuan, down 10.86 percent year on year. Non-GAAP net profit was 113 million yuan, down 32.13 percent year on year. Net cash flow from operating activities was 79.0907 million yuan, down 55.95 percent year on year. Basic earnings per share were 0.39 yuan, and the weighted average return on equity was 4.61 percent. As of the close on August 28, the company's price-to-earnings ratio on a trailing twelve-month basis was about 49.09 times, its price-to-book ratio was about 3.31 times, and its price-to-sales ratio was about 3.34 times. The company is mainly engaged in the research and development, design, production, sales and services of cosmetics.
603983.CG · Capital · Negative First-half net profit fell 10.86% YoY and non-GAAP net profit dropped 32.13%, with operating cash flow down 55.95%.